Veran Medical Technologies, Inc., a lung cancer diagnostic company that enables physicians to diagnose early-stage lung cancer, received a $20M investment from BTG, a global healthcare company focused on Interventional Medicine.

“We are excited to announce BTG’s investment in Veran and look forward to collaborating with them,” said Veran Medical CEO Jason Pesterfield. “BTG and Veran have the shared goal of helping physicians diagnose and treat lung cancer earlier in order to save lives.”

Veran’s SPiN Thoracic Navigation System™ is a revolutionary technology that helps speed time to diagnosis and provides pinpoint thoracic guidance for lifesaving therapies for lung cancer patients. The SPiN System™ provides best in class cancer treatment providers with a scalable platform solution that can also be utilized for managing other leading cancers like liver and kidney cancers.

“We are pleased to enter into this partnership with Veran and support the company’s growth,” said Peter Pattison, BTG’s Head of Interventional Oncology. “Veran’s technology supports the shift towards minimally invasive treatment of lung cancer, an area of strategic interest to BTG.”

“Injustice anywhere is a threat to justice everywhere...We are caught in an inescapable network of mutuality, tied in a single garment of destiny. Whatever affects one directly, affects all indirectly.” –MLK, Jr

Kicking things off at #AdobeSummit2019 with Partner Day! @AdobePartner @AdobeSummit #DialogTech

Ethically Designing Healthy Relationships
New Group Now Open for Enrollment in Durham!

This group helps participants explore polyamorous & consensual non-monogamous relationships.
https://t.co/k81HhIM8qX

We look forward to seeing everyone this week in #LasVegas! Don't forget to visit booth #967. If you would like to schedule a meeting with our team, you can send an email to events@dialogtech.com. #AdobeSummit #DialogTech #Voice